AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Breath Biopsies 2019: A Revolutionary Approach for Noninvasive Diagnosis - ResearchAndMarkets.com

November 22, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 22, 2019--

The “Breath Biopsies: A Revolutionary Approach for Noninvasive Diagnosis” report has been added to ResearchAndMarkets.com’s offering.

Report Includes:

  • Detailed discussion on the breath as a snapshot of an individuals’ health
  • Assessment of the role of breath biopsy in drug development, diagnosis, and treatment of respiratory diseases, cancer, metabolic disorders, and CNS diseases
  • Discussion about proton-transfer-reaction time-of-flight mass spectrometry (PTR-ToF-MS), gas chromatography time-of-flight mass spectrometers (GC-TOF-MS) and field asymmetric ion mobility spectrometry (FAIMS)
  • Coverage of latest developments in-breath biopsy research & analysis and strategies adopted by institutes and start-up companies to identify and enhance breath biopsy in drug development

Summary

In the future, a variety of conditions may be diagnosed with a simple breath test. Researchers are looking beyond blood tests and solid/liquid biopsies to find other sources of information to diagnose disease. Every time an individual breathes, thousands of volatile organic compounds (VOCs) and volatile fatty acids (VFAs), the breakdown products of lipids and proteins,1 are released into the breath. These novel biomarkers are by-products of metabolism, and can provide a snapshot of an individual’s health.

Key Topics Covered:

Chapter 1 Monitoring Volatile Organic Compounds

  • Introduction
  • Analyst’s Credentials
  • Custom Research
  • Related Reports

Chapter 2 Value Proposition of Breath Testing

  • Value Proposition of Breath Testing
  • Technological Advances in Analytical Techniques
  • Technological Advances in Breath Collection

Chapter 3 Applications in Diagnostics

  • Identifying Food Intolerances
  • Guiding Asthma Treatment Decisions
  • Early Detection of Gastroesophageal and Lung Cancer
  • Diagnosing of Liver Disease and Personalizing Treatment
  • Breath Biopsy Could Revolutionize MS Diagnosis
  • Challenges for the Future Development of Breath Biopsies
  • The Future for Breath Biopsies

Chapter 4 Companies and Technologies for Which to Watch Out

  • Algernon Pharmaceuticals
  • Bedfont Scientific Breath Analyzers
  • Breath Diagnostics OneBreath Test
  • Cairn Diagnostics’ 13C-Spirulina GEBT
  • Circassia’s NIOX range
  • Ekips Technologies Breathmeter
  • Exalenz Biosciences’ BreathID Systems
  • Menssana Research’s BreathLink
  • Metabolic Solutions Gut-Chek
  • New England Breath Technologies Glucair
  • Owlstone Medical’s ReCIVA

Chapter 5 References

For more information about this report visit https://www.researchandmarkets.com/r/vhlmxq

View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005194/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/22/2019 06:09 AM/DISC: 11/22/2019 06:09 AM

http://www.businesswire.com/news/home/20191122005194/en